Equities Analysts Set Expectations for CRSP Q3 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Research analysts at Brookline Capital Management issued their Q3 2025 earnings estimates for shares of CRISPR Therapeutics in a research note issued to investors on Tuesday, February 11th. Brookline Capital Management analyst L. Cann forecasts that the company will earn ($0.94) per share for the quarter. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q4 2025 earnings at ($1.09) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday. JMP Securities reiterated a “market outperform” rating and set a $86.00 target price on shares of CRISPR Therapeutics in a research report on Thursday. Barclays increased their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research report on Wednesday. Chardan Capital decreased their target price on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Needham & Company LLC reiterated a “buy” rating and set a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $74.05.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $43.49 on Thursday. The stock has a market capitalization of $3.71 billion, a price-to-earnings ratio of -15.37 and a beta of 1.67. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10. The firm’s 50 day simple moving average is $42.06 and its 200-day simple moving average is $46.25.

Insider Transactions at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Wilmington Savings Fund Society FSB purchased a new position in shares of CRISPR Therapeutics during the 3rd quarter worth $40,000. Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth about $43,000. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics during the 4th quarter worth about $39,000. Western Pacific Wealth Management LP increased its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the last quarter. Finally, Eastern Bank acquired a new stake in shares of CRISPR Therapeutics during the 3rd quarter worth about $70,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.